stockrowargenex SE
ARGX Healthcare Biotechnology
argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024.
- Revenue
- +52.1%
- EPS
- +43.9%
- Free cash flow
- +537.5%
Quarter to September 2026, against a year earlier
Follow ARGX
Alert me
argenex SE (ARGX) Return on equity
argenex SE's return on equity over the twelve months to 30 September 2026 was 0.00%, down 20.2 percentage points from fiscal 2025 (20.2%). Over the past ten years it has ranged from −42.7% (fiscal 2020) to 20.2% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 20.2% | 2.79 |
| FY2024 | 17.4% | 25.90 |
| FY2023 | −8.54% | 18.00 |
| FY2022 | −26.5% | (7.14) |
| FY2021 | −19.4% | 23.29 |
| FY2020 | −42.7% | (22.55) |
| FY2019 | −20.1% | (4.79) |
| FY2018 | −15.4% | (1.55) |
| FY2017 | −13.8% | (4.06) |
| FY2016 | −9.74% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 18.4% |
| REGN Regeneron Pharmaceuticals, Inc. compare | 15.0% |
| GMAB Genmab A/S Sponsored ADR compare | 14.0% |
| INCY Incyte Corporation compare | 7.84% |
| ARGX argenex SE | 0.00% |
| RPRX Royalty Pharma PLC compare | 0.00% |
| ROIV Roivant Sciences Ltd. compare | −5.47% |
| MRNA Moderna, Inc. compare | −39.0% |
| RVMD Revolution Medicines, Inc. compare | −93.6% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ARGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement